Showing 1871-1880 of 2652 results for "".
- Novartis: Two-Year Head-to-Head Data for Brolucizumab Reaffirm Superiority vs Aflibercept in Reducing Retinal Fluid in Patients With Wet AMDhttps://modernod.com/news/novartis-two-year-head-to-head-data-for-brolucizumab-reaffirm-superiority-vs-aflibercept-in-reducing-retinal-fluid-in-patients-with-wet-amd/2479727/Novartis announced additional brolucizumab phase 3 results from year 2 (96 weeks) that reaffirmed its positive year 1 (48 weeks) findings. Brolucizumab met its primary endpoint of noninferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal out
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- CooperVision Releases Four-Year Data on Landmark MiSight 1-Day Contact Lens Studyhttps://modernod.com/news/coopervision-releases-four-year-data-on-landmark-misight-1-day-contact-lens-study/2479840/New 4-year study data shows the significant impact of a pioneering contact lens management approach to slowing the progression of myopia in children, including those whose treatment begins later. CooperVision recently presented the multi-year study’s latest outcomes during the
- OD-OS to Celebrate 10 Years of the Navilas Laser Systems at EURETINAhttps://modernod.com/news/od-os-to-celebrate-10-years-of-the-navilas-laser-systems-at-euretina/2479864/OD-OS, the inventor of the Navilas laser systems, is celebrating 10 years of retina navigation with expert sessions at the upcoming EURETINA 2018 conference in Vienna, September 21-25, booth C207. <
- CooperVision Releases 4-Year Data on Landmark MiSight 1-Day Contact Lens Studyhttps://modernod.com/news/coopervision-releases-4-year-data-on-landmark-misight-1-day-contact-lens-study/2479874/New 4-year study data shows the the impact of a pioneering contact lens management approach to slowing the progression of myopia in children, including those whose treatment begins later, according to a CooperVision news release. CooperVision is presenting the multi-year study’s latest out
- A Contact Lens Was Embedded in Woman’s Eyelid for 28 Yearshttps://modernod.com/news/a-contact-lens-was-embedded-in-womans-eyelid-for-28-years/2479936/Imagine going to the eye doctor because your upper eyelid is swollen and painful. The doctor tells you it’s a cyst and operates. Inside the blister, the surgeon finds a contact lens: a rigid gas-permeable one.
- Mount Sinai Researchers Discover How to Restore Vision Using Retinal Stem Cellshttps://modernod.com/news/mount-sinai-researchers-discover-how-to-restore-vision-using-retinal-stem-cells/2479939/Researchers at Mount Sinai have successfully restored vision in mice through activating retinal stem cells, something that has never been done before. Their study, published in the August 15 online issue of Nature, could transform treatment for patients with retinal degenerative diseases
- Allergan Lifts Earnings Target, Says No Drug Price Hikes This Yearhttps://modernod.com/news/allergan-lifts-earnings-target-says-no-drug-price-hikes-this-year/2479979/Allergan raised its yearly earnings forecast on Thursday thanks to rising sales of mainstay product Botox, and said it did not expect to increase drug prices this year, according to a
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at ASRShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-to-be-presented-at-asrs/2480032/EyePoint Pharmaceuticals announced that three abstracts supporting the company’s YUTIQ (fluocinolone acetonide intravitreal implant) 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the 36th Annual Scientific Meeting of the American Soci